New influenza vaccines were developed to improve vaccine effectiveness by expanding influenza B coverage and boosting hemagglutinin (HA) concentration. This research aims to assess the health impact of the new vaccines – high dose (HD) and quadrivalent influenza vaccines (IIV4), instead of IIV3, in adults aged 65 and older under Ontario’s Universal Influenza Immunization Program (UIIP).